Jiaoti Huang

This study shows that combining enzalutamide with DRP-104 enhances anti-tumor immunity by reducing Treg cells and improving CD8+ T cell activity in prostate cancer.

This paper introduces a nanofluid that enhances laser lithotripsy efficiency while maintaining safety by improving optical absorption and reducing thermal damage.

This study validates BCL-2 as a therapeutic target in CRPC by showing its upregulation under AR inhibition and demonstrating efficacy of BCL-2 inhibitors in preclinical and clinical models.

This study shows that IL-18-armored STEAP1 CAR T cells effectively treat Ewing sarcoma with reduced dose and improved efficacy.

This paper identifies NUAK2 as a therapeutic target in AR-indifferent prostate cancer, showing trilaciclib inhibits NUAK2 and suppresses tumor growth.

This study investigates how cancer cells adapt to purine shortage stress and identifies vulnerabilities in purine metabolism and microtubules as therapeutic targets.

The paper identifies a novel marker gene set, CDHu40, for neuroendocrine prostate cancer (NEPC) using gene expression and PPI network analysis, showing strong prognostic significance.